市況評論

作者

倪國權先生 (Alex Ni)
助理經理

曾任職鋼材交易員及廣告公司主任,所以特別喜歡研究資源類及消費類股票。歡迎來電賜教或交流心得。
電話:
2280 7366

Modern Dental Group Limited (3600.HK)

2019年6月25日 星期二 觀看次數454

Stock Commentary                                     Date: 18/6/2019

        

Stock:                                                     Modern Dental Group Limited

Closing price:                                      $1.46 (18/02/2019)

52 weeks range:                                         $1.186 - $2.017

Shares outstanding:                               986,746,000

Market Capitalization:                         HK$ 1.233 Billion

Target Price (12 months):                        No Target

 

Summary :

  1. The group is in the transition phase period, consolidating their business through various acquisitions.
  2. The incurred loss was from restructuring, re-financing and currency exchange. The group’s core business remained relatively stable.
  3. The group’s prospect came from local market penetration through their strategic geographical acquisitions.
  4. Greater China may be the company’s next sales engine as GDP per capita increased, so was the demand for high quality medical/dental care products.

 

Closer Look of 2018 and beyond:

1.

A. The group’s total sales in dollar value as well as volume record a slight increase; notably, dollar unit of each item also record an increase over the past year.

 

2.

B. The group’s main sale driver came from “Fixed prosthetic devices”. As pointed out from the group’s annual report, the group will continue to focus on high value products in order increase their profit margin.

 

3.

C. European market continued to be the main sales driver of the group’s revenue, while greater China market continued to grow. Recent acquisition in USA would take time to consolidate.

4. Further analysis will be give after the next quarter result in order to get a closer look of the group’s performance.

 

「註:本人倪國權為證監會持牌人士。截至本評論文章發表日止,本人及/或其有聯繫者並無持有全部提及之証券的所有相關財務權益。」; Or
” I, Ni Kwok Kuen Alex, am a licensed person under the Securities and Futures Commission. Until the date this commentary was published, neither I and/or my affiliates are the beneficiary of the securities mentioned herein or are entitled to any financial interests in relation thereto. “

 

 

研究報告由輝立証券集團旗下於香港證監會持牌的輝立証券(香港)有限公司及/ 或輝立商品有限公司(“輝立”)所發報。本文所包含的資料均為輝立從相信為準確的來源搜集。輝立對有關報告所引致之任何損失或虧損概不負責。本報告所載的資料只供参考用途,並沒有法律約束力,亦不構成投資建議、邀約、購入、出售任何產品。
投資涉及風險,有可能損失投資本金。你應諮詢專業人士,就本身的投資經驗、財務狀況、個人目標及風險取向,以提供投資意見。各類產品的風險,請參閱本公司網頁 http://www.phillip.com.hk《風險披露聲明》。
輝立(或其僱員) 可能持有本文所述有關的投資產品。此外,輝立(或任何附屬公司)隨時可能替向報告內容所述及的公司提供服務、招攬或業務往來。
以上資料為輝立擁有並受版權及知識產權法保護。除非事先得到輝立明確書面批准,否則不應複製、散播或發佈。
返回頁首
聯絡我們
請即聯絡你的客戶主任或致電我們。
研究部
電話 : (852) 2277 6846
傳真 : (852) 2277 6565
電郵 : businessenquiry@phillip.com.hk

查詢及支援
分行資料
投訴程序
查數網
登入
黃師傅每日講股
研究部快訊
免費訂閱
聯絡我們